LIFEVANTAGE CORP Share-based Payment Arrangement, Decrease for Tax Withholding Obligation
LIFEVANTAGE CORP (LFVN) reported Share-based Payment Arrangement, Decrease for Tax Withholding Obligation of $3.62 million for the 12-month period ending 2026-06-30, per its 10-K filed 2026-08-27.
Financial Statements › Notes › Equity › Stockholders' Equity Note
us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation · last filed 2026-08-27
- LIFEVANTAGE CORP share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2026-06-30 was $65.00K.
- LIFEVANTAGE CORP share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2026-03-31 was $103.00K, a 86.64% decline year-over-year.
- LIFEVANTAGE CORP share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2025-12-31 was $164.00K, a 81.74% decline year-over-year.
- LIFEVANTAGE CORP share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2025-09-30 was $3.28M, a 846.40% increase year-over-year.
- LIFEVANTAGE CORP share-based payment arrangement, decrease for tax withholding obligation for fiscal 2026 was $3.62M, a 35.74% increase from fiscal 2025.
- LIFEVANTAGE CORP share-based payment arrangement, decrease for tax withholding obligation for fiscal 2025 was $2.66M, a 118.18% increase from fiscal 2024.
- LIFEVANTAGE CORP share-based payment arrangement, decrease for tax withholding obligation for fiscal 2024 was $1.22M, a 507.46% increase from fiscal 2023.
- LIFEVANTAGE CORP share-based payment arrangement, decrease for tax withholding obligation for fiscal 2023 was $201.00K, a 18.29% decline from fiscal 2022.
| Period end | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 3 month | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 6 month | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 9 month | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 12 month |
|---|---|---|---|---|
| 2026-06-30 | $65.00K derived: 10-K 12 month − 3 quarters · filed 2026-08-27 | $168.00K derived: sum of 2 quarters · filed 2026-08-27 | $332.00K derived: sum of 3 quarters · filed 2026-08-27 | $3.62M 10-K · filed 2026-08-27 |
| 2026-03-31 | $103.00K 10-Q · filed 2026-05-06 | $267.00K derived: sum of 2 quarters · filed 2026-05-06 | $3.55M derived: sum of 3 quarters · filed 2026-05-06 | |
| 2025-12-31 | $164.00K 10-Q · filed 2026-05-06 | $3.45M derived: sum of 2 quarters · filed 2026-05-06 | ||
| 2025-09-30 | $3.28M 10-Q · filed 2026-05-06 | |||
| 2025-06-30 | $2.66M 10-K · filed 2026-08-27 | |||
| 2025-03-31 | $771.00K 10-Q · filed 2026-05-06 | $1.67M derived: sum of 2 quarters · filed 2026-05-06 | $2.02M derived: sum of 3 quarters · filed 2026-05-06 | |
| 2024-12-31 | $898.00K 10-Q · filed 2026-05-06 | $1.25M derived: sum of 2 quarters · filed 2026-05-06 | ||
| 2024-09-30 | $347.00K 10-Q · filed 2026-05-06 | |||
| 2024-06-30 | $1.22M 10-K · filed 2025-09-04 | |||
| 2024-03-31 | $233.00K 10-Q · filed 2025-05-06 | $446.00K derived: sum of 2 quarters · filed 2025-05-06 | $911.00K derived: sum of 3 quarters · filed 2025-05-06 | |
| 2023-12-31 | $213.00K 10-Q · filed 2025-05-06 | $678.00K derived: sum of 2 quarters · filed 2025-05-06 | ||
| 2023-09-30 | $465.00K 10-Q · filed 2025-05-06 | |||
| 2023-06-30 | $201.00K 10-K · filed 2024-08-28 | |||
| 2023-03-31 | $54.00K 10-Q · filed 2024-05-02 | $73.00K derived: sum of 2 quarters · filed 2024-05-02 | $145.00K derived: sum of 3 quarters · filed 2024-05-02 | |
| 2022-12-31 | $19.00K 10-Q · filed 2024-05-02 | $91.00K derived: sum of 2 quarters · filed 2024-05-02 | ||
| 2022-09-30 | $72.00K 10-Q · filed 2024-05-02 | |||
| 2022-06-30 | $246.00K 10-K · filed 2023-08-28 | |||
| 2022-03-31 | $31.00K 10-Q · filed 2023-05-04 | $62.00K derived: sum of 2 quarters · filed 2023-05-04 | $201.00K derived: sum of 3 quarters · filed 2023-05-04 | |
| 2021-12-31 | $31.00K 10-Q · filed 2023-05-04 | $170.00K derived: sum of 2 quarters · filed 2023-05-04 | ||
| 2021-09-30 | $139.00K 10-Q · filed 2023-05-04 | |||
| 2021-06-30 | $1.42M 10-K · filed 2022-08-23 | |||
| 2021-03-31 | $126.00K 10-Q · filed 2022-05-03 | $792.00K derived: sum of 2 quarters · filed 2022-05-03 | $1.30M derived: sum of 3 quarters · filed 2022-05-03 | |
| 2020-12-31 | $666.00K 10-Q · filed 2022-05-03 | $1.17M derived: sum of 2 quarters · filed 2022-05-03 | ||
| 2020-09-30 | $506.00K 10-Q · filed 2022-05-03 | |||
| 2020-06-30 | $6.25M 10-K · filed 2022-08-23 | |||
| 2020-03-31 | $1.67M 10-Q · filed 2021-04-29 | $6.03M derived: sum of 2 quarters · filed 2021-04-29 | $6.09M derived: sum of 3 quarters · filed 2021-04-29 | |
| 2019-12-31 | $4.36M 10-Q · filed 2021-04-29 | $4.42M derived: sum of 2 quarters · filed 2021-04-29 | ||
| 2019-09-30 | $61.00K 10-Q · filed 2021-04-29 | |||
| 2019-06-30 | $3.17M 10-K · filed 2021-08-19 | |||
| 2019-03-31 | $193.00K 10-Q · filed 2019-05-01 | $3.17M derived: sum of 2 quarters · filed 2019-05-01 | ||
| 2018-12-31 | $2.97M 10-Q · filed 2019-05-01 | |||
| 2018-06-30 | $0.00 10-K · filed 2020-08-18 | |||
| 2015-12-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2016-02-09 | $0.00 10-Q · filed 2016-02-09 | ||
| 2015-09-30 | $0.00 10-Q · filed 2015-11-04 | |||
| 2015-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-05-06 | $0.00 10-Q · filed 2015-05-06 | ||
| 2014-12-31 | $0.00 10-Q · filed 2015-02-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |